What happened with INO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Inovio Pharmaceuticals develops DNA medicines for HPV-associated diseases, cancer and infectious diseases, paired with its CELLECTRA delivery devices. These devices use electrical pulses to help DNA enter cells, a process called electroporation. Its current priority is seeking U.S. approval and preparing to commercialize INO-3107 for recurrent respiratory papillomatosis, a disease involving recurring growths in the respiratory tract.
The company has no products approved for human use and no commercial product sales. It earns limited revenue from licensing and research agreements, with ApolloBio accounting for all its latest reported revenue. ApolloBio holds exclusive rights to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan.
INOVIO needs additional financing to complete development and bring products to market. Future product sales depend on clinical evidence and regulatory approval of both the medicine and its delivery device; it cannot sell the combination without authorization for both parts.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
INOVIO’s prospects hinge on INO-3107 approval, commercialization and financing, with Nykode adding competition in recurrent respiratory papillomatosis (RRP) outside this list.
Precigen already sells Papzimeos in the United States for adults with recurrent respiratory papillomatosis, competing directly for the patients INOVIO seeks to treat with INO-3107. Watch Papzimeos patient uptake and insurance coverage: Precigen is building its market while INOVIO still needs approval and commercialization before expecting material product revenue.
PDS Biotechnology Corporation competes with INOVIO in developing treatments that use the immune system against HPV-associated cancers, so its clinical progress matters to the same treatment markets. PDS has not generated product revenue through its 2025 reporting period; its HPV-cancer trial progress, rather than sales, is the relevant comparison for INOVIO.
BioNTech competes with INOVIO in investigational immune-based treatments for HPV-associated cancers, despite their different vaccine platforms. BioNTech sells the COVID-19 vaccine Comirnaty, but its HPV-cancer clinical progress—not those vaccine sales—is what to watch for this rivalry.
Inovio Pharmaceuticals, Inc. earningsThis company
INOVIO’s report will show whether spending to advance INO-3107 is using cash faster than the company’s stated runway allows.
Read the cash balance alongside cash used in operations, and check whether INOVIO is still concentrating resources on INO-3107. Slower cash use with that focus intact would better support the company’s stated runway into the fourth quarter of 2026. Faster cash use or a sharper drop in cash would mean the plan depends more on new financing and may face delays or cuts.
Precigen, Inc. earningsPGEN
Precigen’s report will show how Papzimeos use and insurance coverage are developing among U.S. patients with recurrent respiratory papillomatosis, the market INOVIO hopes to enter with INO-3107.
Look for patient use of Papzimeos alongside what Precigen reports about insurance coverage. Growing use and broader coverage would show an established treatment building a market that INO-3107 would have to win over if approved. Limited progress would show less commercial traction for Papzimeos, but would not prove patients will choose INO-3107.
